Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1243
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 481–492 of 1,243 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

NCT06100705
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone Cypionate, Sipuleucel-T
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Not applicable Interventional

I-DECIDE After Bronchiolitis Hospitalization

NCT07243652
Status at this site: Recruiting
View directory record Official record
Conditions
Bronchiolitis Acute
Interventions
Moderate-Resource Implementation Strategy, High-Resource Implementation Strategy
Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Months to 24 Months
Enrollment
2,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
60
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Not applicable Interventional

Peru Decentralized HIV Care

NCT05910268
Status at this site: Not yet recruiting
View directory record Official record
Conditions
HIV
Interventions
NIATx + ECHO
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Active, not recruiting Phase 1 Interventional

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

NCT07223983
Site status not listed — check the official record
View directory record Official record
Conditions
Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients
Interventions
Semaglutide 1.0 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
51
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder

NCT05957159
Status at this site: Recruiting
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Detoxification Program, PKAB, CFN
Other · Radiation
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Phase 2 Interventional

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

NCT07216391
Status at this site: Recruiting
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Antithymocyte Globulin (ATG), Teplizumab
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 34 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

NCT06999434
Status at this site: Recruiting
View directory record Official record
Conditions
Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy
Interventions
[ 18F]3F4AP, [18F]MK6240, [11C]PIB
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Recruiting Phase 1 Interventional

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

NCT07387068
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
GEN1079
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Not yet recruiting Not applicable Interventional

Facial Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

NCT07810764
Site status not listed — check the official record
View directory record Official record
Conditions
Facial Vascularized Composite Allotransplantation, Functional Recovery
Interventions
Facial Vascularized Composite Allotransplantation (VCA)
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2037
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00972478
Site status not listed — check the official record
View directory record Official record
Conditions
Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate, Vorinostat
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
190
States / cities
Mobile, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 132 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:16 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Therapeutic Hypothermia in Patients With ARDS

NCT04545424
Site status not listed — check the official record
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 85 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 10:16 AM EDT

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.